apixaban
Selected indexed studies
- Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. (Clin Pharmacokinet, 2019) [PMID:31089975]
- Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. (Circulation, 2022) [PMID:36335914]
- Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. (Blood Adv, 2022) [PMID:34662890]
_Worker-drafted node — pending editorial review._
Connections
apixaban is a side effect of
Sources
- Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. (2019) pubmed
- Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. (2022) pubmed
- Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. (2022) pubmed
- Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial‡. (2022) pubmed
- Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. (2020) pubmed
- Apixaban for Anticoagulation After Robotic Mitral Valve Repair. (2023) pubmed
- Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. (2023) pubmed
- Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. (2018) pubmed
- Apixaban for Children With Heart Disease. (2023) pubmed
- Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study. (2024) pubmed